|View printer-friendly version|
|Illumina Files Patent Infringement Suit Against BGI in Denmark|
“As we have previously stated,
The complaint alleges that BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 3 002 289 B1. This patent covers Illumina’s proprietary sequencing-by-synthesis chemistry. The complaint also alleges that BGI’s use of the MGISEQ mark infringes Illumina’s registered EU Trademark No. 8972127 for the MISEQ name.
Earlier this year,
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.